The Aetna Innovation Labs were created to test specific initiatives, determine success rates and impact, and expand programs that show promise.
Aetna has created a dedicated team it calls the Aetna Innovation Labs to research the practices that have the greatest potential to improve patient outcomes or demonstrate measurable value to customers, healthcare providers or members. The labs will allow Aetna to test specific initiatives such as those related to disease prediction and intervention, determine success rates and impact across populations of members, and expand programs that show promise.
The marketplace is rapidly changing,” said Michael Palmer, head of the Aetna Innovation Labs. “Forces such as healthcare reform, emerging technologies and economic conditions are driving our need to constantly develop innovative and measurable programs to improve healthcare quality and reduce costs for our customers and members.”
Palmer joined Aetna from Accenture, where he was global managing partner of medical technology.
In one of its first projects, the Aetna Innovation Labs is working to make cancer care more effective, more affordable and safer by deploying technology including the eviti clinical decision-support program. The company is making eviti available through its data exchange and applications platform, iNexx, and launching the program in New York and New Jersey.
A second project being undertaken by the Aetna Innovation Labs combines “big data” provided by Aetna with a supercomputer-enabled platform from GNS Healthcare with the goal of analyzing it to rapidly discover what types of interventions drive better outcomes in those who are at-risk for metabolic syndrome, and for whom these interventions work best.
“Aetna Innovation Labs is currently focused on clinical and platform innovation and on improving member and provider engagement,” Palmer said. “But we are exploring a number of different areas that will drive value, from next-generation platforms, to telehealth and mHealth (mobile health), to genomics. We will likely also launch new businesses based on the work of Aetna Innovation Labs to both strengthen our core offerings and provide new capabilities to our customers.”
Go back to the Managed Healthcare Executive eNews newsletter.
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
Study Raises Concerns Over Insurance Barriers to HIV Prevention Medications
November 29th 2023Despite its efficacy, PrEP remains underutilized compared to the need for it. High costs are among the barriers to PrEP use, along with limited knowledge among clinicians, lack of health insurance, stigma, and underestimation of personal HIV risk.
Read More
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen